Ravi Salgia, MD, PhD
Ravi Salgia M.D., Ph.D., is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences at City of Hope’s comprehensive cancer center.
Prior to joining City of Hope, Dr. Salgia served as tenured professor of medicine, pathology and dermatology; director of the Thoracic Oncology Program and the Aerodigestive Tract Program Translational Research Lab in the section of hematology/oncology; vice chair for translational research in the department of medicine; and associate director for translational science at the University of Chicago Comprehensive Cancer Center in Chicago.
RDr. Salgia earned his undergraduate summa cum laude in mathematics, biologyand chemistry, and then his medical doctorate and Ph.D. from Loyola University in Chicago, where he also completed fellowships in neurochemistry and physiology. He continued his postgraduate training with an internship and residency in internal medicine at The Johns Hopkins Hospital in Baltimore, followed by a fellowship in medical oncology at Dana-Farber Cancer Institute in Boston, during which time he also served as a clinical fellow at HarvardMedical School in Boston
Board-certified in medical oncology, Dr. Salgia serves on various panels for the National Cancer Institute.He has consistently received research grants from the National Institutes of Healthfor his research work and has been awarded several invention discoveries and patents related to his work. He is the co-chief editor for theJournal of Carcinogenesis.Dr. Salgia also serves on the editorial advisory board of four additional journals. He has authored over 375 peer-reviewed articles, reviews and editorials, one bookand over 30 book chapters.
Dr. Salgia is frequently invited to present his work at national and international conferences and symposia, and is the recipient of several honors and awards including πμε National Competition in Mathematics, Richard V. Andree Award for “Volume of an n-Dimensional Unit Sphere”; 2016 Asclepius Award from the Bonnie J. Addario Lung Cancer Foundation; IACA Award for Outstanding Contributions to Oncology; served as member of NIH/NCI’s Tumor Progression and Metastasis Study Section; and CONC Study Section; and he is also a member of the Thoracic Malignancy Steering Committee of the NCI.
